Ten-year follow-up of radiation therapy oncology group protocol 92-02: A phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer
Ten-year follow-up of radiation therapy oncology group protocol 92-02: A phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer
复制标题
DOI：
10.1200/jco.2007.14.9021
复制
发表时间：
2008-05-20
影响因子：
45.3
通讯作者：
Shipley, William U.
中科院分区：
文献类型：
--
作者：
Horwitz, Eric M.;Bae, Kyounghwa;Shipley, William U.
PurposeTo确定是否增加2年的雄激素剥夺治疗（ADT）改善患者的结局选择性治疗ADT之前和期间的放射治疗（RT）patients and MethodsProstate cancer patients with T2 c-T4 prostate cancer with no extra pelvic lymph node involvement and prostate specific antigen（PSA）less than 150 ng/mL。所有患者在RT前和RT期间均接受了4个月的戈舍瑞林和氟替卡松治疗。他们被随机分配至无进一步ADT（短期ADT [STAD] + RT）或24个月的戈舍瑞林（长期ADT [LSD] + RT）。共有1,554名患者入组。盆腔淋巴结RT为45戈伊，前列腺RT为65 ~ 70戈伊。两组所有存活患者的中位随访时间分别为11.31和11.27年。结果在10年时，除总生存期外，LVD + RT组的所有终点均显著优于STAD + RT组：（13.2% vs22.5%; P < .0001），疾病特异性生存率（83.9% vs88.7%; P = .0042），局部进展（22.2% vs12.3%; P < .0001），远处转移（22.8% vs14.8%; P < .0001），
PurposeTo determine whether adding 2 years of androgen-deprivation therapy (ADT) improved outcome for patients electively treated with ADT before and during radiation therapy (RT).Patients and MethodsProstate cancer patients with T2c-T4 prostate cancer with no extra pelvic lymph node involvement and prostate-specific antigen (PSA) less than 150 ng/mL were included. All patients received 4 months of goserelin and flutamide before and during RT. They were randomized to no further ADT (short-term ADT [STAD] + RT) or 24 months of goserelin (long-term ADT [LTAD] + RT). A total of 1,554 patients were entered. RT was 45 Gy to the pelvic nodes and 65 to 70 Gy to the prostate. Median follow-up of all survival patients is 11.31 and 11.27 years for the two arms.ResultsAt 10 years, the LTAD + RT group showed significant improvement over the STAD + RT group for all end points except overall survival: disease-free survival (13.2% v 22.5%; P < .0001), disease-specific survival (83.9% v 88.7%; P = .0042), local progression (22.2% v 12.3%; P < .0001), distant metastasis (22.8% v 14.8%; P